Biotech

All Articles

Actinogen's cortisol blocker stops working phase 2 anxiety research study

.Actinogen Medical's cortisol blocker has actually missed out on the key endpoint of a period 2 stud...

Bivictrix makes a decision going exclusive only method to take ADC right into medical clinic

.Antibody-drug conjugates (ADCs) have gone to the facility of several a billion-dollar biobuck licen...

TPG bests up funds to $580M for investments across life sciences

.Resource supervisor TPG, which has actually assisted biotechs such as Sionna Rehabs as well as Sant...

Merck ceases period 3 TIGIT trial in bronchi cancer cells for impossibility

.Merck &amp Co.'s TIGIT plan has actually endured one more drawback. Months after shuttering a stage...

After a tough year, Exscientia folds in to Recursion

.After a year described by pipeline cuts, the departure of its CEO as well as layoffs, Exscientia wi...

Cullinan, after $25M bargain, restore bispecific to Port

.Cullinan Therapeutics was blown away good enough with Harbour BioMed's bispecific immune activator ...

A more detailed examine Brutal Biotech's Tough 15

.In this full week's episode of "The Top Line," our experts are actually diving in to Intense Biotec...

Lilly encounters stage 2 failure of tau-targeting med

.The confetti is still flying coming from Eli Lilly's celebration commemorating the commendation of ...

Biogen CMO Maha Radhakrishnan joins Sofinnova-- Chutes &amp Ladders

.Welcome to today's Chutes &amp Ladders, our roundup of significant management hirings, firings and ...

Lykos will certainly inquire FDA to reexamine its own selection observing turndown of MDMA therapy for trauma

.Complying with an inadequate revealing for Lykos Therapeutics' MDMA applicant for trauma at a lates...